NEWS

30

2025-10

Imviva Biotech Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CTD402 in Relapsed/Refractory T-ALL/LBL

30

2025-10

Imviva Biotech Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA313 for Patients with Autoimmune Diseases at ACR Convergence 2025

28

2025-10

ACR 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA311 and CTA313 for Patients with Autoimmune Diseases

16

2025-06

EHA 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Universal CAR-T Therapy CTD402 for Patients with R/R T-ALL/LBL

01

2025-06

ASCO 2025 | Bioheng Therapeutics Presents Positive Clinical Data of the Universal CAR-T Product RD06-03 in R/R B-ALL

June 1, 2025 , Bioheng Therapeutics, an innovative biopharmaceutical company focused on the development and commercialization of cell therapies, presented results from an investigator-initiated trial (IIT) of RD06-03, its allogeneic anti-CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

< 123 >

Contact Us

Consult Now